Emergent Biosolutions Revenue 2007-2021 | EBS

Emergent Biosolutions revenue from 2007 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Emergent Biosolutions Annual Revenue
(Millions of US $)
2020 $1,555
2019 $1,106
2018 $782
2017 $561
2016 $489
2015 $489
2014 $404
2013 $313
2012 $282
2011 $273
2010 $286
2009 $235
2008 $179
2007 $183
2006 $153
2005 $131
Emergent Biosolutions Quarterly Revenue
(Millions of US $)
2021-06-30 $398
2021-03-31 $343
2020-12-31 $583
2020-09-30 $385
2020-06-30 $395
2020-03-31 $193
2019-12-31 $360
2019-09-30 $312
2019-06-30 $243
2019-03-31 $191
2018-12-31 $271
2018-09-30 $174
2018-06-30 $220
2018-03-31 $118
2017-12-31 $194
2017-09-30 $149
2017-06-30 $101
2017-03-31 $117
2016-12-31 $152
2016-09-30 $143
2016-06-30 $91
2016-03-31 $103
2015-12-31 $141
2015-09-30 $158
2015-06-30 $126
2015-03-31 $64
2014-12-31 $102
2014-09-30 $138
2014-06-30 $110
2014-03-31 $54
2013-12-31 $98
2013-09-30 $89
2013-06-30 $82
2013-03-31 $43
2012-12-31 $95
2012-09-30 $67
2012-06-30 $70
2012-03-31 $50
2011-12-31 $108
2011-09-30 $59
2011-06-30 $88
2011-03-31 $19
2010-12-31 $103
2010-09-30 $74
2010-06-30 $62
2010-03-31 $47
2009-12-31 $54
2009-09-30 $43
2009-06-30 $73
2009-03-31 $65
2008-12-31 $36
2008-09-30 $57
2008-06-30 $43
2008-03-31 $43
2007-12-31 $90
2007-09-30 $44
2007-06-30 $23
2007-03-31 $26
2006-12-31 $87
2006-09-30 $42
2006-06-30 $11
2006-03-31 $12
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.813B $1.555B
Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining the trust of their customers, employees and shareholders. The foundation of the corporate governance principles and practices are built on their reputation for openness, integrity and accountability. These are the principles that guide Emergent BioSolutions everyday. They have in place policies and practices to ensure that their Company is managed with integrity and in their shareholders' best interests. In addition, they are committed to meeting the requirements of federal and state law and the rules of the New York Stock Exchange.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29